Evidence of enhancement of the ras oncogene protein product (p21) in a spectrum of human tumors

✍ Scribed by F. De Biasi; G. Del Sal; P. Horan Hand

• Publisher: John Wiley and Sons
• Year: 1989
• Tongue: French
• Weight: 592 KB
• Volume: 43
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910430315

✦ Synopsis

Using a direct binding liquid competition radioimmunoassay, the amount of the ras oncogene protein product, p2 I, was quantitated in a variety of human tumors and adjacent apparently normal tissues. In 48 of 50 matched tumor and normal tissue biopsy specimens from 50 patients, more ras p2I was detected in the tumor than in its normal counterpart. Twenty-five of 28 breast tumors demonstrated more ras p2 I than the average of the values obtained for fibroadenomas. Furthermore, in I 7 of the I9 cases studied, over 20% more ras p21 was observed in breast carcinomas compared with their respective normal counterparts. More ras p21 was also demonstrated in the majority of tumors of the stomach, lung, colon and bladder compared with their respective adjacent normal tissues. Our data therefore indicate that ras p2I expression is quantitatively enhanced in many human tumors originating from several different tissue types.